Last reviewed · How we verify
Vaginal conjugated estrogen cream 0.5gm
Estrogen replacement therapy to alleviate menopausal symptoms.
Estrogen replacement therapy to alleviate menopausal symptoms. Used for Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause or breast cancer treatment.
At a glance
| Generic name | Vaginal conjugated estrogen cream 0.5gm |
|---|---|
| Also known as | Premarin |
| Sponsor | TriHealth Inc. |
| Drug class | estrogen replacement therapy |
| Modality | Small molecule |
| Therapeutic area | Women's Health |
| Phase | Phase 3 |
Mechanism of action
Vaginal conjugated estrogen cream works by releasing estrogen directly into the vagina, which helps to alleviate symptoms of menopause such as vaginal dryness and pain during sex. This is achieved by mimicking the natural estrogen levels in the body, promoting healthy vaginal tissue and reducing inflammation.
Approved indications
- Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause or breast cancer treatment
Common side effects
- Vaginal bleeding
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaginal conjugated estrogen cream 0.5gm CI brief — competitive landscape report
- Vaginal conjugated estrogen cream 0.5gm updates RSS · CI watch RSS
- TriHealth Inc. portfolio CI